AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

NVST · NYSE · Medical - Instruments & Supplies

Envista

Provides dental technologies, consumables, and services through a multi-brand portfolio.

$27.00

After-hours close−0.14 (−0.52%)

At close$27.14(−1.09%)

Something off on this page? Send us feedback.

Profile

Envista Holdings CorpNVSTHealth Care

Combines dental technologies, consumables, and services across brands including DEXIS, Kerr, Nobel Biocare, and Ormco. The portfolio is organized between Specialty Products & Technologies and Equipment & Consumables and operates with the Envista Business System.

Brings together more than 30 dental brands, including DEXIS, Kerr, Nobel Biocare, and Ormco, under an independent company created from Danaher's dental platform. Its Specialty Products & Technologies and Equipment & Consumables businesses sell dental technologies, consumables, and services.

Uses the Envista Business System as its foundational operating methodology, with a culture it says is supported by CIRCLe Values. The company maintains the operating model transferred from Danaher while running its dental portfolio as a separate public company.

Completed its IPO and separation from Danaher in 2019; Danaher retained no voting or economic interest in its common stock after the separation.

Company facts

CEOPaul Keel

ListedSep 18, 2019

ExchangeNYSE

HeadquartersBrea, CA

CountryUnited States

Employees12,000

CIK0001757073

ISINUS29415F1049

Key statistics

Market cap$4.41B

EPS (ttm)$0.5800

P/E (ttm)46.78

ROE4.1%

P/B1,427,801.90

P/S1.55

Dividend yield—

Beta1.28vs XLV 0.75

Year to date +25.1% · Average volume (30d) 2.8M

Analysts

Price target, next 12 months$29.00+6.9%Median of 19 analysts · vs the Aug 28 close

ConsensusHold7 of 19 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $27.13

High$34.00+25.3%

Median$29.00+6.9%

Low$23.00−15.2%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Aug 6, 2026	Morgan Stanley	Target		$19	$23
Aug 6, 2026	Robert W. Baird	Target		$31	$34
Aug 6, 2026	Mizuho Securities	Target		$24	$29
Jul 29, 2026	Piper Sandler	Reiterate	Neutral	$25	$26
Jul 8, 2026	BMO Capital	Initiate	Market Perform		$27

Earnings

EPS

Estimate$0.36

ReportedDue Nov 4, 2026

Revenue

Estimate$695.9M

ReportedDue Nov 4, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 5, 2026Q2 FY26	$0.34	$0.41	+22.3%	$716.1M	$730.5M	+2.0%	−4.37%
May 6, 2026Q1 FY26	$0.31	$0.36	+16.1%	$680.0M	$705.5M	+3.7%	−10.27%
Feb 5, 2026Q4 FY25	$0.32	$0.38	+18.8%	$680.0M	$750.6M	+10.4%	+17.77%
Oct 29, 2025Q3 FY25	$0.27	$0.32	+18.5%	$680.3M	$669.9M	−1.5%	+0.80%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$616.9M	$682.1M	$669.9M	$750.6M	$705.5M	$730.5M
Gross profit	$336.0M	$370.2M	$375.1M	$413.1M	$390.1M	$407.0M
Operating income	$39.0M	$50.8M	$64.8M	$75.8M	$62.5M	$80.3M
Net income	$18.0M	$26.4M	−$30.3M	$32.9M	$38.7M	$53.7M
Diluted EPS	$0.10	$0.16	−$0.18	$0.20	$0.23	$0.33
Gross margin	54.5%	54.3%	56.0%	55.0%	55.3%	55.7%
Operating margin	6.3%	7.4%	9.7%	10.1%	8.9%	11.0%

Fiscal years (4-quarter sums)FY21 $2.51B · FY22 $2.57B · FY23 $2.57B · FY24 $2.51B · FY25 $2.72B

Revenue by product · FY24

Specialty Products And Technologies$1.62B · 64%

Equipment And Consumables$894.2M · 36%

Revenue by geography · Q2 FY26

North America$364.7M · 69%

Western Europe$165.3M · 31%

Balance sheet, Jul 3, 2026Cash & short-term investments — · Total debt $1.6K · Total assets — · Shareholders' equity —

Dividends

No dividends on record.

Ownership

Institutions 120.67%Insiders 0.87%

A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.

Shares outstanding 162.73M · Float 162.02M · 99.6% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
BlackRock, Inc.	18.44M	11.33%	13F	Aug 7, 2026
Ariel Investments, LLC	9.82M	6.03%	13F	Aug 14, 2026
Dimensional Fund Advisors LP	9.57M	5.88%	13F	Aug 11, 2026
Vanguard Portfolio Management LLC	7.49M	4.60%	13F	Aug 13, 2026
Vanguard Capital Management LLC	7.34M	4.51%	13F	Aug 13, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 20, 2026	Mischa Reis	officer: SVP, Strategy & Bus. Dev.	−8,000	$27.50
Feb 10, 2026	Mischa Reis	officer: SVP, Strategy & Bus. Dev.	−5,634	$30.00